Skip to content

Use of nalbuphine drug as an additive with 0.5 percent levobupivacaine for upper limb orthopedic surgery in ultrasound guided supraclavicular block.

Study on the effect of nalbuphine as an adjuvant to 0.5% levobupivacaine in ultrasound guided supraclavicular Brachial Plexus Block - Nil

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/07/055741
Enrollment
80
Registered
2023-07-26
Start date
Unknown
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: NALBUPHINE ADDED TO 0.5% LEVOBUPIVACAINE: ONE GROUP NALBUPHINE 1ML ADDED TO 0.5% LEVOBUPIVACAINE 20ML AND OTHER GROUP 0.5% LEVOBUPIVACAINE20 ML WITH 1ML NORMAL SALINE Intervention2: ULT

Sponsors

School of Medical Science And Research And Sharda Hospital, Greater Noida
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients undergoing elective upper limb surgery. 2. Age between 18 to 65 years. 3. ASA physical status class 1 and 2

Exclusion criteria

Exclusion criteria: 1. Patients with a history of allergy or hypersensitivity to either local anaesthetic or opioid drugs. 2. Pregnancy 3. Patients with coagulation disorders 4. Local infection at the site of injection 5. Patients who are taking any antipsychotics

Design outcomes

Primary

MeasureTime frame
To compare the duration of analgesic effect in two groups.Timepoint: 24 hours

Secondary

MeasureTime frame
1. To compare onset & duration of block in the two groups. (a) onset & duration of sensory block (b) onset & duration of motor block 2. To compare the rescue analgesic requirements in the two groups. 3. To compare the incidence of side effects & to observe the incidence of complication in the two groups. Timepoint: 24 hours

Countries

India

Contacts

Public ContactDr Harsh Vardhan

School of Medical Science And Research

Harsh.vardhan1@sharda.ac.in9871952687

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026